4 completed. 3 Phase 3, 1 Phase 2.
By phase and status
Follow Pertuzumab IV: new trials by email Literature Review of Pertuzumab IV trials Research Report on Pertuzumab IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV - Early Breast Cancer, Locally Advanced Breast Cancer Phase 3 Completed Hoffmann-La Roche 346 2022-07-05 2026-02-10 A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer Pertuzumab IV, Trastuzumab IV, Pertuzumab and Trastuzumab FDC SC - HER2-positive Early Breast Cancer Phase 3 Completed Hoffmann-La Roche 200 2020-02-05 2026-02-20 A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV - HER2-Positive Early Breast Cancer Phase 2 Completed Hoffmann-La Roche 160 2018-12-19 2024-01-02 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Cyclophosphamide, Doxorubicin, Docetaxel - Early Breast Cancer Phase 3 Completed Hoffmann-La Roche 500 2018-06-14 2024-06-26
Conditions studied Breast Neoplasms (2) · Inflammatory Breast Neoplasms (1) · Patient Preference (1)
Sponsors Hoffmann-La Roche (4)
Countries Argentina (3) · Brazil (3) · Mexico (3) · Spain (3) · Canada (2) · Chile (2) · South Korea (2) · United States (2) · Belgium (1) · Bosnia and Herzegovina (1) · Bulgaria (1) · China (1) · Costa Rica (1) · Croatia (1) · Cuba (1)
Results publications PMID 33357420 , PMID 34147014 , PMID 40461387
NIH funding 2017 (1), 2018 (1), 2023 (1)